Protalix BioTherapeutics (PLX) Cash from Investing Activities (2010 - 2026)
Protalix BioTherapeutics' quarterly Cash from Investing Activities came in at $4.2 million in Q1 2026, up 1453.53% year-on-year from $271833.3 in Q1 2025, and up 479.77% quarter-over-quarter from -$1.1 million in Q4 2025.
Protalix BioTherapeutics has reported Cash from Investing Activities for 17 years, with the latest figure at $4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 1453.53% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 51.96% YoY), and the FY2025 full-year result was -$2.4 million, down 156.05% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $4.2 million, up from -$1.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $20.3 million in Q3 2024, with the low at -$20.9 million in Q3 2023.
- Average Cash from Investing Activities over 5 years is -$921647.1, with a median of -$312000.0 recorded in 2025.
- Year-over-year, Cash from Investing Activities slumped 4379.53% in 2024 and soared 1453.53% in 2026.
- Tracing PLX's Cash from Investing Activities over 5 years: stood at $5.0 million in 2022, then plunged by 106.9% to -$342000.0 in 2023, then tumbled by 4379.53% to -$15.3 million in 2024, then jumped by 92.74% to -$1.1 million in 2025, then jumped by 479.77% to $4.2 million in 2026.
- The last three Cash from Investing Activities figures came in at $4.2 million (Q1 2026), -$1.1 million (Q4 2025), and -$504000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 4.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.22 Mn |
| Mar 31, 2026 | 4.22 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Sep 30, 2025 | -504,000.00 |
| Sep 30, 2025 | -504,000.00 |
| Jun 30, 2025 | -438,000.00 |
| Jun 30, 2025 | -438,000.00 |
| Mar 31, 2025 | -312,000.00 |
| Mar 31, 2025 | -312,000.00 |
| Dec 31, 2024 | -15.32 Mn |
| Dec 31, 2024 | -15.32 Mn |
| Sep 30, 2024 | 20.33 Mn |
| Sep 30, 2024 | 20.33 Mn |
| Jun 30, 2024 | -180,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -606,000.00 |
| Mar 31, 2024 | -606,000.00 |
| Dec 31, 2023 | -342,000.00 |
| Dec 31, 2023 | -342,000.00 |
| Sep 30, 2023 | -20.88 Mn |
| Sep 30, 2023 | -20.88 Mn |
| Jun 30, 2023 | -222,000.00 |
| Jun 30, 2023 | -222,000.00 |
| Mar 31, 2023 | 4.73 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 4.95 Mn |
| Dec 31, 2022 | 4.95 Mn |
| Sep 30, 2022 | 5.91 Mn |
| Sep 30, 2022 | 5.91 Mn |
| Jun 30, 2022 | 357,000.00 |
| Jun 30, 2022 | 357,000.00 |
| Mar 31, 2022 | -16.26 Mn |
| Mar 31, 2022 | -16.26 Mn |
| Dec 31, 2021 | 37.44 Mn |
| Dec 31, 2021 | 37.44 Mn |
| Sep 30, 2021 | 4.63 Mn |
| Sep 30, 2021 | 4.63 Mn |
| Jun 30, 2021 | 7.54 Mn |
| Jun 30, 2021 | 7.54 Mn |
| Mar 31, 2021 | -30.68 Mn |
| Mar 31, 2021 | -30.68 Mn |
| Dec 31, 2020 | 7.59 Mn |
| Dec 31, 2020 | 7.59 Mn |
| Sep 30, 2020 | 7.80 Mn |
| Sep 30, 2020 | 7.80 Mn |
| Jun 30, 2020 | -268,000.00 |
| Jun 30, 2020 | -268,000.00 |
| Mar 31, 2020 | -35.08 Mn |
| Mar 31, 2020 | -35.08 Mn |
| Dec 31, 2019 | 29,000.00 |
| Dec 31, 2019 | 29,000.00 |
| Sep 30, 2019 | -446,000.00 |
| Sep 30, 2019 | -446,000.00 |
| Jun 30, 2019 | -95,000.00 |
| Jun 30, 2019 | -95,000.00 |
| Mar 31, 2019 | -371,000.00 |
| Mar 31, 2019 | -371,000.00 |
| Dec 31, 2018 | 84,000.00 |
| Dec 31, 2018 | 84,000.00 |
| Sep 30, 2018 | -228,000.00 |
| Sep 30, 2018 | -228,000.00 |
| Jun 30, 2018 | -119,000.00 |
| Jun 30, 2018 | -119,000.00 |
| Mar 31, 2018 | -328,000.00 |
| Mar 31, 2018 | -328,000.00 |
| Dec 31, 2017 | -34,000.00 |
| Dec 31, 2017 | -34,000.00 |
| Sep 30, 2017 | -116,000.00 |
| Sep 30, 2017 | -116,000.00 |
| Jun 30, 2017 | -686,000.00 |
| Jun 30, 2017 | -686,000.00 |
| Mar 31, 2017 | -283,000.00 |
| Mar 31, 2017 | -283,000.00 |
| Dec 31, 2016 | -242,000.00 |
| Dec 31, 2016 | -242,000.00 |
| Sep 30, 2016 | -66,000.00 |
| Sep 30, 2016 | -66,000.00 |
| Jun 30, 2016 | -366,000.00 |
| Jun 30, 2016 | -366,000.00 |
| Mar 31, 2016 | -293,000.00 |
| Mar 31, 2016 | -293,000.00 |
| Dec 31, 2015 | 39.90 Mn |
| Dec 31, 2015 | 39.90 Mn |
| Sep 30, 2015 | -169,000.00 |
| Sep 30, 2015 | -169,000.00 |
| Jun 30, 2015 | -248,000.00 |
| Jun 30, 2015 | -248,000.00 |
| Mar 31, 2015 | -99,000.00 |
| Mar 31, 2015 | -99,000.00 |
| Mar 31, 2014 | -370,000.00 |
| Mar 31, 2014 | -370,000.00 |
| Dec 31, 2013 | -271,000.00 |
| Dec 31, 2013 | -271,000.00 |
| Sep 30, 2013 | -419,000.00 |
| Sep 30, 2013 | -419,000.00 |
| Jun 30, 2013 | -723,000.00 |
| Jun 30, 2013 | -723,000.00 |
| Mar 31, 2013 | -689,000.00 |
| Mar 31, 2013 | -689,000.00 |
| Dec 31, 2012 | -376,000.00 |
| Dec 31, 2012 | -376,000.00 |
| Sep 30, 2012 | -819,000.00 |
| Sep 30, 2012 | -819,000.00 |
| Jun 30, 2012 | -239,000.00 |
| Jun 30, 2012 | -239,000.00 |
| Mar 31, 2012 | -852,000.00 |
| Mar 31, 2012 | -852,000.00 |
| Dec 31, 2011 | -747,000.00 |
| Dec 31, 2011 | -747,000.00 |
| Sep 30, 2011 | -1.03 Mn |
| Sep 30, 2011 | -1.03 Mn |
| Jun 30, 2011 | -1.44 Mn |
| Jun 30, 2011 | -1.44 Mn |
| Mar 31, 2011 | -2.65 Mn |
| Mar 31, 2011 | -2.65 Mn |
| Dec 31, 2010 | -1.08 Mn |
| Dec 31, 2010 | -1.08 Mn |
| Sep 30, 2010 | -1.38 Mn |
| Sep 30, 2010 | -1.38 Mn |